All News
Filter News
Found 2,297 articles
-
Medidata Experts Present New Insights on Risk-Based Quality Management, Decentralized Clinical Trials, and Real World Data at SCOPE Summit
2/3/2023
Medidata, a Dassault Systèmes company, will be leading multiple sessions at the upcoming Summit for Clinical Ops Executives (SCOPE) on trial diversity, risk based quality management (RBQM), decentralized clinical trials (DCT), real world data, sensors and wearables, and randomization and trial supply management (RTSM).
-
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
2/2/2023
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022.
-
Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger
2/2/2023
Sesen Bio, Inc. filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc.
-
Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023
2/2/2023
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 23, 2023 to report its fourth quarter and full year 2022 financial results, and provide a corporate update.
-
Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment
2/1/2023
Ratio Therapeutics Inc. announces the close of its Series A financing extension today, bringing the total raised to date to over $40 million.
-
The FDA granted Moderna's RSV vaccine candidate Breakthrough Therapy Designation Monday.
-
Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
1/30/2023
Moderna, Inc. today announced mRNA-1345, an investigational mRNA vaccine candidate for respiratory syncytial virus (RSV), has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) in adults aged 60 years or older.
-
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
1/26/2023
CytomX Therapeutics, Inc. today announced that it achieved a clinical candidate milestone under its TCB agreement with Astellas.
-
Myosana Therapeutics Raises $5 Million in Seed Funding
1/25/2023
Myosana Therapeutics, Inc. today announced the completion of a seed funding round totaling over $5 million led by investor John Ballantyne, Ph.D.
-
Johnson & Johnson discontinued the Phase III trial of an investigational HIV vaccine regimen Wednesday after an independent review showed it was ineffective at preventing disease.
-
DM Clinical Research Opens New Research Site in Boston Area
1/19/2023
DM Clinical Research, a national network of clinical trial sites, has opened its first research location in the Boston metropolitan area and Massachusetts.
-
Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics
1/19/2023
Sesen Bio, Inc. announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company’s pending merger with Carisma Therapeutics Inc., a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies.
-
Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults
1/17/2023
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of mRNA-1345, an investigational mRNA vaccine targeting respiratory syncytial virus (RSV) in older adults.
-
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference
1/17/2023
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the B. Riley Securities Virtual Annual Oncology Investor Conference on Thursday, January 19, 2023 at 2:30 p.m. ET.
-
The drugmaker's presentation highlights its strong revenue growth, dominant vaccine business and expanding oncology portfolio.
-
JPM Day 1: Highlights
1/9/2023
Stay on top of what's happening at JPM. BioSpace is covering all the key announcements all week. -
Moderna Announces Advances Across mRNA Pipeline and Provides Business Update
1/9/2023
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced updates on its industry-leading mRNA pipeline. Moderna continues to scale, now with 48 programs in development, including 36 programs in clinical trials encompassing mRNA infectious disease vaccines and mRNA therapeutics spanning seven different modalities.
-
Moderna and CytomX ink a cancer partnership.
-
Ginkgo Bioworks Expands Its R&D Facilities, Opens Bioworks7 to Conduct Mammalian Screening at Scale, Widening Capabilities for Biopharma Partners
1/6/2023
Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced the opening of Bioworks7, the latest expansion of its biological engineering foundry.
-
Metagenomi announced a Series B extension financing round led by Moderna, Leaps by Bayer and several others.